ANAB

ANAB

Last Updated:

Q3 '20

AnaptyBio Inc

AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.

Cash

$338.3M

Burn Rate (Qtr)

$23.8M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Imsidolimab

Generalized Pustular Psoriasis (GPP)

FDA end-of-Phase 2 meeting with FDA

Q4 2020

Etokimab (ANB020) Anti-IL-3

Eosinophilic Asthma

Phase 2b On hold

Etokimab (ANB020) Anti-IL-33

Chronic Rhinosinusitis with Nasal Polyps

Phase 2 Readout

Q4 2020

Imsolimab (anti-IL-36R) (ANB019)

Palmoplantar Pustulosis

Phase 2 Top-Line Data

Q1 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon